Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 2

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

Authors Thomas X

Received 16 November 2011

Accepted for publication 17 January 2012

Published 5 March 2012 Volume 2012:2 Pages 57—76

DOI https://doi.org/10.2147/BLCTT.S15567

Review by Single-blind

Peer reviewer comments 3


Xavier Thomas

Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Hématologie Clinique, Pavillon Marcel Bérard, Bât.1G, Pierre Bénite, France

Abstract: The choice of treatment approach in acute leukemia depends on well-established prognostic factors. A number of features can predict the outcome of treatment including cytogenetics and an increasing list of molecular features. These are increasingly being used to direct postinduction therapy and support risk-adapted treatments that should achieve optimal results while minimizing nonrelapse mortality. In addition, they are also molecular targets for a new generation of small molecule inhibitors that are in early development and promise to further improve outcomes in the coming decade.

Keywords: acute myeloid leukemia, acute lymphoblastic leukemia, treatment, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]